Haan, JD; van de Kreeke, JA; van Berckel, BN; Barkhof, F; Teunissen, CE; Scheltens, P; Verbraak, FD; Haan, JD; van de Kreeke, JA; van Berckel, BN; Barkhof, F; Teunissen, CE; Scheltens, P; Verbraak, FD; Bouwman, FH; - view fewer (2019) Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring , 11 pp. 383-391. 10.1016/j.dadm.2019.03.006.

Preview

Text Barkhof_Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease_VoR.pdf - Published Version Download (1MB) | Preview

Abstract

INTRODUCTION: The retina is a potential source of noninvasive vascular biomarkers for Alzheimer's disease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking ophthalmological confounders into account. METHODS: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively normal control subjects. All participants underwent ophthalmological screening to exclude interfering ocular disease. Using a multimodal approach, we measured retinal vascular parameters, choroidal thickness, macular vascular density, and foveal avascular zone size. RESULTS: We found no disease effects on retinal vascular measures (all β′s < |0.15|, all P > .2), adjusted for confounders. Venular tortuosity was inversely associated with Fazekas score in control subjects (β −0.56, P < .01), while vessel density in the outer ring of the macula was inversely associated with Fazekas score in AD cases (β −0.64, P < .01). DISCUSSION: In conclusion, retinal vasculature did not discriminate patients with AD from control subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers, challenging the use of retinal vasculature measurements as AD biomarker.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as CSVJSONXML

Downloads by country - last 12 months

Export as XMLJSONCSV

Archive Staff Only

View Item